http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오늘 본 자료
紅蔘과 白蔘의 成分상 비교연구 : Amino acid에 대하여
韓大錫 세계평화교수협의회 1976 아카데미論叢 Vol.4 No.1
The red ginseng and white ginseng which were processed according to current method with 6 years olf fresh ginseng root, Kimpo, Korea, was pulverized. This pulver was dried at 105℃±1℃ for 5hrs. In drying oven and taken as sample. The amounts of rough proteins were measured be Kjeldahl method. The sample and 6N-HCl were packed in capillary tube, and after with nitrogen gas, stoppered. The sample in capillary tube was hydrolyzed by heating at 110℃ for 22hrs. Hydrolized products were filtered and the filterate was concentrated until no HCl is detected. After dilution with sodium citrate buffer solution, amino acid were analysed by amino acid autoanalyser under the conditions of Table1. The amounts of amino acids contained in 100g of dried sample were shown as Table2. 1) The rough protein of red ginseng was richer than white ginseng about 6%. This fact is expected as due to the lixiviation of other components rather than nitrogen containing compounds. 2) The rough proteins of 57% of red ginseng 62% of white ginseng were changed to amino acids. 3) 4 kinds of amino acid such as histidine, arginine, aspartic acid and valine were rich in red ginseng and the remainder of 12 kinds of amino acid were rich in white ginseng.
韓大錫 서울대학교 1968 서울대학교 論文集 Vol.19 No.-
Transvers section of the Lycii Fructus (Kukija) exhibit an outer cuticlar and two layers of collenchymatous cell. The inner region of the collenchymatous cell comprised of about ten layers parenchyma cell which contain numerous red grains considered as Carotenoid. Constituents of above crude drug is following. moisture 21.26% ashes 5.51% acid insoluble ashes 0.73% alcohol extraction 13.57% water extraction 35.83%
신질환이 있는 경증 미치 중등도의 고혈압 환자에서 Irbesartan의 항고혈압효과 및 안전성을 평가하기 위한 제 4상 임상 시험
한대석,송영수,이호영,김주성,윤수영,한승혁,박정엽,김병극,노현정,노현진,신석균,최규헌 대한신장학회 2000 Kidney Research and Clinical Practice Vol.19 No.4
Irbesartan is a new selective angiotensin II subtype 1 receptor antagonist. We evaluated the efficacy and tolerability of irbesartan in patients with mild to moderate hypertension and renal disease. On 24 hypertensive patients, oral irbesartan 150mg a day was administered. In cases whose seated diastolic blood pressure did not decrease to 85mmHg after treatment for 4 weeks, the dose of irbesartan was increased to 300mg per day. Every 4 weeks, blood pressure, heart rates, and adverse effects were monitored. And we assessed WBC counts, hemoglobin, hematocrits, platelets, creatinine, BUN, total protein, albumin, fasting blood sugar, total cholesterol, AST, ALT, alkaline phosphatase, total bilirubin, sodium, potassium, calcium, uric acid and urine protein/creatinine ratio to evaluate the change of renal and hepatic function and other adverse effects. Seated systolic blood pressure was decreased from 157.1±3.1mmHg to 135.5±3.7mmHg, and seated diastolic blood pressure was also decreased frorn 99.2±1.7mmHg to 84..5mmHg. Irbesartan was effective in lowering blood pressure in 20 among 24 patients, and the effective rate of this drug was 83.3%. After treatment, a non clinically significant increase of heart rates and statistically significant decrease of total cholesterol level were noted. There was no doserelated adverse effect. We conclude that irbesartan is a safe and effective angiotensin II subtype 1 receptor antagonist for lowering blood pressure in patients with mild to moderate hyrtension and renal disease.